According to the results of the Pharma & Hospital Report study which analyzes the local pharmaceutical market Cegedim Customer Information estimates that between October 2022-September 2023, the volume of medicines dispensed to patients in Romania was 718.9 mn units, up by 1.8% as compared to the October 2021-September 2022 period.
The total number of treatment days increased by 3.7%. Excluding drugs allocated to the cost-volume-result (CVR) and cost-volume (CV) programs, for prescription-bound medicines in retail and hospitals, the number of treatment days increased by 5.5%.
The value of medicines dispensed to patients in Romania during the same period went up by 16.0%, to RON 28.7 bn (EUR 5.8 bn), at the wholesale price level. By isolating the impact of cost-volume-result (CVR) and cost-volume (CV) programs, the value of Rx medicines in retail pharmacies went up by 19.3% as compared to the previous 12 months, to RON 14.5 bn (EUR 2.9 bn).
Pharma market evolution in Volume and in Value
In the third quarter of 2023, the total volume of the medicines dispensed to patients reached 175.5 mn units, down by 0.2% as compared to the 3rd quarter of 2022. This evolution was generated both by the slight retail decrease (-0.3%), as well as a small hospital increase (+2.6%). By segments, the Rx drugs in pharmacies increased by 4.8% while the OTC products (both OTC drugs and nutritional supplements) decreased by 7.8%.
The total value of the medicines dispensed to patients during the same period reached RON 7.48 bn, up by 13.1% as compared to the same period last year, given that the medicines dispensed in retail went up by 14.4% and those in hospitals by 6.2%. Within the retail channel, Rx medicines advanced by 19.2% and OTCs by 3.3%.
While the retail Rx drugs related to cost-volume contracts increased by 23.7%, in part due to the introduction of new molecules, those for cost-volume-result contracts decreased by 14.9%. The rest of Rx medicines in retail also advanced by 20.3% as compared to 3rd quarter of 2022.
Main players in the local pharmaceutical market
In terms of volumes, in the 3rd quarter of 2023, the hierarchy remained the same, with Sun Pharma (including Terapia) in the first place with 18.4 mnand by Sanofi with RON 349.1 units, followed by Zentiva (including Labormed and Alvogen) with 16.4 mn units and by Servier (including Egis) with 10.6 mn units.
In terms of value, in the 3rd quarter of 2023, there is a change in the hierarchy, with SunPharma (including Terapia) taking first place with RON 357.6 mn, followed by AstraZeneca with RON 351.3 mn and by Sanofi with RON 349.1 mn.
To consult the complete information on the Romanian pharmaceutical market evolution in the third auqrter of 2023 as well as the top players on this market during the same period, access directly our press release.
We also invite you to consult an executive summary of the study for the mentioned period, with graphical representations of the data presented in our article.
Pharma & Hospital Report, a reference study in the analysis of the pharmaceutical market in Romania, has been carried out since 1996.
